The U.S. Food and Drug Administration approved Novo Nordisk’s Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar.
Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.
Southern California-based Sienna Biopharmaceuticals filed for bankruptcy, which sent share prices tumbling more than 73 percent.
The U.S. Food and Drug Administration gave the green light to Johnson & Johnson’s Janssen for Erleada (apalutamide) as a treatment for metastatic castration-sensitive prostate cancer.
Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.
AstraZeneca’s Farxiga was granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the diabetes drug and putting the medicine ahead of rivals.
Biogen Inc. and Eisai Co. Ltd. are abandoning two late-stage trials for their Alzheimer’s treatment elenbecestat in a widely anticipated move that comes months after the companies scrapped studies of aducanumab for the memory-robbing disease.
Researchers from Cold Spring Harbor Laboratory in New York discovered that certain proteins believed essential for the survival of cancer cells – the same proteins that many drugmakers have been targeting – may not be as important after all.
Zelnorm was relaunched by Alfasigma USA for the treatment of irritable bowel syndrome with constipation (IBS-C).
Genentech released full data from the company’s pivotal Phase III SAkuraStar trial of satralizumab as a monotherapy for NMOSD.